Sirnaomics Receives NCI Grant to Develop siRNA-Based Lung Cancer Rx
July 23, 2009
Sirnaomics Receives NCI Grant to Develop siRNA-Based Lung Cancer Rx
The six-month grant began on June 1 and is worth $250,000. The company will use the funds to develop multi-targeted siRNA drugs for non-small cell lung cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sirnaomics Presents Preclinical HPV Data
December 20, 2012 / Gene Silencing News - Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
June 28, 2012 / Gene Silencing News - Tekmira Cleared to Begin Second Phase I Trial of siRNA Cancer Drug
August 11, 2011 / Gene Silencing News - Tekmira, NCI Publish Preclinical Data on siRNA Knockdown of Liver Cancer Target
April 28, 2011 / Gene Silencing News - Tekmira on Track to Start Cancer Rx Trial Before Year-End; Cholesterol Drug Still On Hold
November 18, 2010 / Gene Silencing News